Valdecoxib does not impair platelet function.

Abstract

The platelet effects of a supratherapeutic dose of the new cyclooxygenase (COX)-2 specific inhibitor, valdecoxib (40 mg twice a day), naproxen 500 mg twice a day, diclofenac 75 mg twice a day, and placebo were compared in 62 healthy adult subjects in this 7(1/2) day single-center, randomized, placebo-controlled trial. Platelet aggregation responses (to arachidonate [AA], collagen, and adenosine diphosphate [ADP]), bleeding time, and serum thromboxane B(2) (TxB(2)) concentrations were measured at baseline and at regular intervals on days 1 and 8. Valdecoxib had no effect on platelet function. Naproxen and diclofenac significantly reduced the platelet aggregation response to AA and to a lesser extent collagen and ADP at most assessments compared with placebo. Naproxen significantly lowered serum TxB(2) levels. In contrast to standard doses of 2 nonsteroidal antiinflammatory drugs (NSAIDs), a supratherapeutic valdecoxib dosage does not impair platelet function (COX-1). Valdecoxib may be a safer analgesic option than conventional NSAIDs in patients for whom bleeding complications are a concern. (Am J Emerg Med 2002;20:275-281.

• Authors: Philip T Leese, Sheela Talwalker, Jeffrey D Kent, David P Recker
• Journal: The American journal of emergency medicine (Am J Emerg Med) Vol. 20 Issue 4 Pg. 275-81 (Jul 2002) ISSN: 0735-6757 [Print] United States
• PMID: 12098171 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2002, Elsevier Science (USA). All rights reserved.)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Cyclooxygenase Inhibitors
• Isoxazoles
• Sulfonamides
• Diclofenac
• valdecoxib
• Thromboxane B2
• Naproxen

Topics

• Adolescent
• Adult
• Analysis of Variance
• Anti-Inflammatory Agents, Non-Steroidal (pharmacology)
• Bleeding Time
• Cyclooxygenase Inhibitors (pharmacology)
• Diclofenac (pharmacology)
• Double-Blind Method
• Female
• Humans
• Isoxazoles (pharmacology)
• Male
• Middle Aged
• Naproxen (pharmacology)
• Platelet Aggregation (drug effects)
• Statistics, Nonparametric
• Sulfonamides (pharmacology)
• Thromboxane B2 (blood)